DK1748770T3 - Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen - Google Patents
Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifenInfo
- Publication number
- DK1748770T3 DK1748770T3 DK05716433T DK05716433T DK1748770T3 DK 1748770 T3 DK1748770 T3 DK 1748770T3 DK 05716433 T DK05716433 T DK 05716433T DK 05716433 T DK05716433 T DK 05716433T DK 1748770 T3 DK1748770 T3 DK 1748770T3
- Authority
- DK
- Denmark
- Prior art keywords
- benign breast
- hydroxy tamoxifen
- breast disease
- prevention
- treatment
- Prior art date
Links
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 title abstract 3
- 208000011803 breast fibrocystic disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/805,528 US7507769B2 (en) | 2004-03-22 | 2004-03-22 | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP04290761A EP1579856A1 (en) | 2004-03-22 | 2004-03-22 | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| PCT/EP2005/003286 WO2005092309A1 (en) | 2004-03-22 | 2005-03-10 | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1748770T3 true DK1748770T3 (da) | 2008-08-04 |
Family
ID=34961912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05716433T DK1748770T3 (da) | 2004-03-22 | 2005-03-10 | Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1748770B1 (da) |
| JP (1) | JP5072588B2 (da) |
| CN (1) | CN1946387B (da) |
| AT (1) | ATE391499T1 (da) |
| AU (1) | AU2005227072B2 (da) |
| CA (1) | CA2559748C (da) |
| DE (1) | DE602005005986T2 (da) |
| DK (1) | DK1748770T3 (da) |
| ES (1) | ES2306111T3 (da) |
| MX (1) | MXPA06010914A (da) |
| NO (1) | NO336767B1 (da) |
| NZ (1) | NZ549817A (da) |
| PL (1) | PL1748770T3 (da) |
| PT (1) | PT1748770E (da) |
| RU (1) | RU2357726C2 (da) |
| WO (1) | WO2005092309A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1799201T3 (da) * | 2004-10-14 | 2009-03-30 | Besins Int Lab | 4-Hydroxy-tamoxifen gelformuleringer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2515041A1 (fr) * | 1981-10-26 | 1983-04-29 | Besins Jean | Medicament a base de progesterone pour le traitement des affections mammaires |
| FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| ES2044860T3 (es) * | 1987-04-21 | 1994-01-16 | Heumann Pharma Gmbh & Co | Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno. |
| DE4407742C1 (de) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat |
| CN1320880C (zh) * | 1998-12-23 | 2007-06-13 | 伊迪亚股份公司 | 改进的体内局部无创伤用制剂 |
| RU2188000C1 (ru) * | 2001-09-27 | 2002-08-27 | Нестерук Владимир Викторович | Лекарственное средство на основе тамоксифена |
| DK1317921T3 (da) * | 2001-12-07 | 2009-12-21 | Besins Mfg Belgium | Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf |
| EP1572178B1 (en) * | 2002-12-18 | 2006-05-03 | Laboratoires Besins International | Treatment of mastalgia with 4-hydroxy tamoxifen |
| EP1952809B1 (en) * | 2002-12-18 | 2017-08-02 | Besins Healthcare Luxembourg SARL | Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen |
| ES2483896T3 (es) * | 2003-04-01 | 2014-08-08 | Besins Healthcare Luxembourg Sarl | Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen |
| JP5069469B2 (ja) * | 2003-12-15 | 2012-11-07 | ラボラトワール ブザン アンテルナスィヨナル | 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用 |
-
2005
- 2005-03-10 EP EP05716433A patent/EP1748770B1/en not_active Expired - Lifetime
- 2005-03-10 AU AU2005227072A patent/AU2005227072B2/en not_active Expired
- 2005-03-10 NZ NZ549817A patent/NZ549817A/en not_active IP Right Cessation
- 2005-03-10 CN CN2005800091724A patent/CN1946387B/zh not_active Expired - Lifetime
- 2005-03-10 CA CA2559748A patent/CA2559748C/en not_active Expired - Lifetime
- 2005-03-10 RU RU2006137280/15A patent/RU2357726C2/ru active
- 2005-03-10 ES ES05716433T patent/ES2306111T3/es not_active Expired - Lifetime
- 2005-03-10 WO PCT/EP2005/003286 patent/WO2005092309A1/en not_active Ceased
- 2005-03-10 PT PT05716433T patent/PT1748770E/pt unknown
- 2005-03-10 MX MXPA06010914A patent/MXPA06010914A/es active IP Right Grant
- 2005-03-10 DK DK05716433T patent/DK1748770T3/da active
- 2005-03-10 JP JP2007504377A patent/JP5072588B2/ja not_active Expired - Lifetime
- 2005-03-10 PL PL05716433T patent/PL1748770T3/pl unknown
- 2005-03-10 DE DE602005005986T patent/DE602005005986T2/de not_active Expired - Lifetime
- 2005-03-10 AT AT05716433T patent/ATE391499T1/de active
-
2006
- 2006-10-11 NO NO20064609A patent/NO336767B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005092309A1 (en) | 2005-10-06 |
| DE602005005986D1 (de) | 2008-05-21 |
| NO336767B1 (no) | 2015-10-26 |
| JP2007535505A (ja) | 2007-12-06 |
| ES2306111T3 (es) | 2008-11-01 |
| RU2006137280A (ru) | 2008-04-27 |
| NO20064609L (no) | 2006-10-11 |
| AU2005227072A1 (en) | 2005-10-06 |
| CN1946387B (zh) | 2011-08-31 |
| MXPA06010914A (es) | 2006-12-15 |
| EP1748770B1 (en) | 2008-04-09 |
| EP1748770A1 (en) | 2007-02-07 |
| AU2005227072B2 (en) | 2010-08-19 |
| CA2559748A1 (en) | 2005-10-06 |
| ATE391499T1 (de) | 2008-04-15 |
| PL1748770T3 (pl) | 2008-09-30 |
| CA2559748C (en) | 2013-05-28 |
| JP5072588B2 (ja) | 2012-11-14 |
| DE602005005986T2 (de) | 2009-06-04 |
| HK1096595A1 (en) | 2007-06-08 |
| RU2357726C2 (ru) | 2009-06-10 |
| NZ549817A (en) | 2010-06-25 |
| PT1748770E (pt) | 2008-07-16 |
| CN1946387A (zh) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05010597A (es) | Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. | |
| EA201791669A3 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| NZ746784A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| Cohen et al. | The bright side of ascites in ovarian cancer | |
| SE0300098D0 (sv) | Use of cyclin D1 inhibitors | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| DE60320398D1 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
| EA200700273A1 (ru) | Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана | |
| RU2017129056A (ru) | Антигистаминное средство для применения для лечения рака молочной железы | |
| NO20062904L (no) | Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti | |
| NO20064609L (no) | Behandling og forhindring av godartet brystsykdom med 4-hydroksytamoksifen | |
| AR025718A1 (es) | Metodo para reducir el riesgo de cancer | |
| Krco et al. | Priapism due to solid malignancy | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| He et al. | Priapism as the initial manifestation of a penile and lower limb cutaneous metastasis of prostate adenocarcinoma with low serum PSA level | |
| Rieder et al. | Primary squamous cell carcinoma in unreconstructed exstrophic bladder | |
| DE602006019759D1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
| RU2004116477A (ru) | Применение n, n-диэтил-2-[4-(фенилметил)фенокси]этанамина моногидрохлорида (dppe) при лечении раковых заболеваний | |
| RU2008107113A (ru) | Средство и способ профилактики и лечения пациентов с болезнью альцгеймера |